NCT00407550 - Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

May 12, 2010

Conditions

Lung Cancer

Interventions

DRUG

gemcitabine HCL

1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.

DRUG

pemetrexed disodium

500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.

DRUG

gemcitabine HCL

1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.

Trial Locations (1)

55905

Mayo Clinic Cancer Center, Rochester